Clinical Trial

Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated September 15, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study is a single-arm prospective cohort study designed to evaluate the efficacy and safety of triple therapy (ADT + darolutamide + docetaxel) combined with transrectal high-intensity focused ultrasound (HIFU) focal therapy in patients with high-tumor-burden metastatic hormone-sensitive prostate cancer (mHSPC). A total of 116 high-tumor-burden mHSPC patients will be enrolled and are scheduled to receive the following treatment: Darolutamide + Docetaxel + ADT + Transrectal HIFU Focal Therapy for the Prostate.
Trial Details
NCT Number NCT07172685
Lead Sponsor Qilu Hospital of Shandong University
Conditions Prostate Cancer
Enrollment 116 participants
Start Date 2025-07-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-09-15